Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to cancer detection, and University of Chicago today announce the publication of a genome-wide 5-hydroxymethylcytosine (5hmC) map across multiple human tissue types. The study, published in the peer-reviewed journal Nature Communications, demonstrated the robust performance of 5hmC as a global biomarker for the detection of multiple serious illnesses, such as cancer and various chronic diseases.
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of 'financial toxicity,' reports a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer, suggests a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
In a promising advance for affordable, personalised medicine, researchers have used metal-organic frameworks to successfully deliver the genetic snipping tool CRISPR/Cas9 into human cancer cells.
"The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer."
Prostate cancer is caused by elevated hormone levels, and tumours are generally treated using hormone therapy. A research team headed by Lukas Kenner of MedUni Vienna in collaboration with David Heery from the University of Nottingham/UK and Sarka Pospisilova and Suzanne Turner of the University of Brno/Czech Republic have shown that the protein μ-crystallin (CRYM) plays a significant part in tumour growth. The higher the levels of this protein that are present, the better the prognosis.
In a secondary analysis of VITAL, a team led by investigators at Brigham and Women's Hospital has narrowed in on the connection between taking vitamin D supplements and risk of metastatic or fatal cancer. In a paper published in JAMA Network Open, the team reports that vitamin D was associated with an overall 17 percent risk reduction for advanced cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"--either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Prolonged androgen deprivation therapy (ADT) can impair cardiorespiratory fitness and increase risk of cardiovascular death in prostate cancer patients with high risk of cardiovascular disease, according to a study in JACC: CardioOncology. The findings contribute further data supporting the need for cardiovascular disease (CVD) monitoring in patients who are living longer after successful cancer treatment.
Columbia researchers have identified a gene signature in localized prostate cancer that predicts the cancer's odds of spreading and its response to a common treatment for advanced disease.